KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 377-381

  Borrelli, Nicla ^a   Giannini, Riccardo ^a   Proietti, Agnese ^b   Alì, Greta ^b   Pelliccioni, Serena ^b   Niccoli, Cristina ^b   Lucchi, Marco ^b   Melfi, Franca ^b   Mussi, Alfredo ^a   Basolo, Fulvio ^a,b   Fontanini, Gabriella ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Adenocarcinoma; Cytology; Fluorescent in situ hybridization; KIF5B RET rearrangement; Lung; Reverse transcriptase polymerase chain reaction; Solid

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; PARAFFIN; PROTEIN RET; RNA;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CYTOLOGY; EML4 ALK FUSION GENE; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; FUSION GENE; GENE EXPRESSION; GENE FUSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; KIF5B RET FUSION GENE; LUNG ADENOCARCINOMA; MALE; MINIMALLY INVASIVE PROCEDURE; ONCOGENE K RAS; PRIORITY JOURNAL; TISSUE SECTION; WILD TYPE;

ADENOCARCINOMA; CYTOLOGY; FLUORESCENT IN SITU HYBRIDIZATION; KIF5B/RET REARRANGEMENT; LUNG; REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION; SOLID;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSLOCATION, GENETIC;

EID: 84881663252     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.026     Document Type: Article

References (37)

1. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95:1276-1299.
2. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
3. Chuman Y., Bergman A., Ueno T., Saito S., Sakaguchi K., Alaiya A.A., et al. a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999, 462:129-134.
4. Travis W.D.C.T., Corrin B. Hystological typing of lung and pleural tumours 1999, Springer Verlag, Berlin.
5. Smouse J.H., Cibas E.S., Janne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009, 117:67-72.
6. Boldrini L., Ali G., Gisfredi S., Ursino S., Baldini E., Melfi F., et al. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep 2009, 22:683-691.
7. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
8. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
9. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
10. Ju Y.S., Lee W.C., Shin J.Y., Lee S., Bleazard T., Won J.K., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22:436-445.
11. Kohno T., Ichikawa H., Totoki Y., Yasuda K., Hiramoto M., Nammo T., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012, 18:375-377.
12. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18:378-381.
13. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18:382-384.
14. Li F., Feng Y., Fang R., Fang Z., Xia J., Han X., et al. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 2012, 22:928-931.
15. Cai W., Su C., Li X., Fan L., Zheng L., Fei K., et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer 2013, 119:1486-1494.
16. Suehara Y., Arcila M., Wang L., Hasanovic A., Ang D., Ito T., et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012, 18:6599-6608.
17. Yokota K., Sasaki H., Okuda K., Shimizu S., Shitara M., Hikosaka Y., et al. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep 2012, 28:1187-1192.
18. Sasaki H., Shimizu S., Tani Y., Maekawa M., Okuda K., Yokota K., et al. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med 2012, 1:68-75.
19. Drilon A., Wang L., Hasanovic A., Suehara Y., Lipson D., Stephens P., et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013, 3:630-635.
20. Rekhtman N., Brandt S.M., Sigel C.S., Friedlander M.A., Riely G.J., Travis W.D., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011, 6:451-458.
21. Nakajima T., Yasufuku K., Suzuki M., Hiroshima K., Kubo R., Mohammed S., et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007, 132:597-602.
22. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011, 39:D945-D950.
23. Mao C., Qiu L.X., Liao R.Y., Du F.B., Ding H., Yang W.C., et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010, 69:272-278.
24. Riely G.J., Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 2008, 10:493-495.
25. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:201-205.
26. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
27. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
28. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
29. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
30. Antoniu S.A. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703. Expert Opin Ther Targets 2011, 15:351-353.
31. Herbst R.S., Sun Y., Eberhardt W.E., Germonpre P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
32. Dy G.K., Hillman S.L., Rowland K.M., Molina J.R., Steen P.D., Wender D.B., et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010, 116:5686-5693.
33. Novello S., Camps C., Grossi F., Mazieres J., Abrey L., Vernejoux J.M., et al. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol 2011, 6:1260-1266.
34. Schneider B.J., Gadgeel S.M., Ramnath N., Wozniak A.J., Dy G.K., Daignault S., et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 2011, 6:1117-1120.
35. Lee J.S., Hirsh V., Park K., Qin S., Blajman C.R., Perng R.P., et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012, 30:1114-1121.
36. Wang R., Hu H., Pan Y., Li Y., Ye T., Li C., et al. RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer. J Clin Oncol 2012, 30:4352-4359.
37. Pang B., Matthias D., Ong C.W., Dhewar A.N., Gupta S., Lim G.L., et al. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases. Cytopathology 2012, 23:229-236.